Top Markets
#1 Nesa Nesa +787.23%
#2 Cortex Cortex +68.85%
#3 Merlin's Seal BTC Merlin's Seal BTC +45.81%
#4 Pons Pons +28.40%
#5 QuantixAI QuantixAI +23.66%
#6 EXOD EXOD +22.78%
#7 Instadapp Instadapp +19.23%
#8 The Black Bull The Black Bull +14.43%
#9 Magma Finance Magma Finance +12.53%
#10 Movement Movement +11.94%
Coin of the day
Nesa Nesa
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Surrozen, Inc. Surrozen, Inc.

Surrozen, Inc.

SRZN
Classement en actions #19464
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates... Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs’ endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Prix de l'action
$21.57
Dernière synchronisation: 2026-07-31
Capitalisation boursière
$161.29M
Changement (1 jour)
3.55%
Changement (1 an)
94.32%
Pays
US
Échange Surrozen, Inc. (SRZN)

Catégorie

Healthcare
Revenus pour Surrozen, Inc. (SRZN)
Revenus en Aug 2026 TTM : 0
Selon les derniers rapports financiers de Surrozen, Inc., le chiffre d'affaires actuel de l'entreprise (TTM) est de 0. En 2026, l'entreprise a réalisé un chiffre d'affaires de 0 égal à le chiffre d'affaires de l'année 2026, qui était de 0. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Surrozen, Inc. de 2026 à 2026
Revenus à la fin de chaque année
Année Revenus Changez
Pas assez de données pour les dates fournies.
Revenus d’entreprises similaires ou concurrentes
Entreprise Revenus Différence de revenus Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH